Key facts
- This page summarizes Redmile Group, LLC's Form 4 filing for Attovia Therapeutics, Inc. (ATTO).
- 4 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 07 Aug 2026, 21:47.
Redmile Group, LLC - 06 Aug 2026 Form 4 Insider Report for Attovia Therapeutics, Inc. (ATTO)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ATTO
- Reported as of
- 06 Aug 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Aug 2026, 21:47:17 UTC
- Prior SEC filing
- 04 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Redmile Group, LLC filed Form 4 for Attovia Therapeutics, Inc. (ATTO) on 07 Aug 2026.
Change
- Previous filing in this sequence was filed on 04 Aug 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (3)
CIK 0001425738
Primary reporting owner
Redmile Group, LLC
- Relationship
- 10%+ Owner
- Address
- 900 LARKSPUR LANDING CIRCLE, SUITE 270, LARKSPUR
- Signature
- By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC
- Signature date
- 07 Aug 2026
CIK 0001650527
Green Jeremy
- Relationship
- 10%+ Owner
- Address
- C/O REDMILE GROUP, LLC (NY OFFICE), 45 W. 27TH STREET, FLOOR 11, NEW YORK
- Signature
- /s/ Jeremy Green
- Signature date
- 07 Aug 2026
CIK 0001838746
Redmile Biopharma Investments III, L.P.
- Relationship
- 10%+ Owner
- Address
- C/O REDMILE GROUP, LLC, 900 LARKSPUR LANDING CIRCLE, SUITE 270, LARKSPUR
- Signature
- By: /s/ Jeremy Green, Managing Member of Redmile Biopharma Investments III (GP), LLC, general partner of Redmile Biopharma Investments III, L.P.
- Signature date
- 07 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATTO
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +782,854
- Change %
- Price
- Shares after
- 782,854
- Date
- 06 Aug 2026
- Ownership
- See footnotes
- Footnotes
- F1, F2, F4
ATTO
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +782,854
- Change %
- Price
- Shares after
- 782,854
- Date
- 06 Aug 2026
- Ownership
- See footnotes
- Footnotes
- F1, F2, F4
ATTO
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +782,854
- Change %
- Price
- Shares after
- 782,854
- Date
- 06 Aug 2026
- Ownership
- See footnotes
- Footnotes
- F1, F2, F4
ATTO
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +200,000
- Change %
- +26%
- Price
- $17.00*
- Shares after
- 982,854
- Date
- 06 Aug 2026
- Ownership
- Direct
- Footnotes
- F2, F4
ATTO
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +200,000
- Change %
- +26%
- Price
- $17.00*
- Shares after
- 982,854
- Date
- 06 Aug 2026
- Ownership
- Direct
- Footnotes
- F2, F4
ATTO
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +200,000
- Change %
- +26%
- Price
- $17.00*
- Shares after
- 982,854
- Date
- 06 Aug 2026
- Ownership
- Direct
- Footnotes
- F2, F4
ATTO
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +400,000
- Change %
- +51%
- Price
- $17.00*
- Shares after
- 1,182,854
- Date
- 06 Aug 2026
- Ownership
- See footnotes
- Footnotes
- F3, F4
ATTO
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +400,000
- Change %
- +51%
- Price
- $17.00*
- Shares after
- 1,182,854
- Date
- 06 Aug 2026
- Ownership
- See footnotes
- Footnotes
- F3, F4
ATTO
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +400,000
- Change %
- +51%
- Price
- $17.00*
- Shares after
- 1,182,854
- Date
- 06 Aug 2026
- Ownership
- See footnotes
- Footnotes
- F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATTO
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -782,854
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 06 Aug 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 782,854
- Exercise price
- Footnotes
- F1, F2, F4
ATTO
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -782,854
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 06 Aug 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 782,854
- Exercise price
- Footnotes
- F1, F2, F4
ATTO
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -782,854
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 06 Aug 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 782,854
- Exercise price
- Footnotes
- F1, F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Redmile Group, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
On August 6, 2026, the Series B Preferred Stock converted by its terms in full automatically into shares of the Issuer's common stock, upon the consummation of the Issuer's initial public offering ("IPO"), for no consideration. The Series B Preferred Stock had no expiration date.
Footnote F2
These securities are held directly by Redmile Biopharma Investments III, L.P. ("RBI III"), which is managed by Redmile Group, LLC ("Redmile"). RBI III disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that RBI III is the beneficial owner of the reported securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Footnote F3
These securities were purchased in the IPO by certain private investment vehicles managed by Redmile (collectively, the "Redmile Clients"), and include the number of securities purchased by RBI III in the IPO reported in the line above.
Footnote F4
Redmile may be deemed to beneficially own the reported securities as the investment manager of RBI III and the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose.